Details of the Drug Combination

General Information of Drug Combination (ID: DC6BKTF)

Drug Combination Name

Indazole derivative 5 Picoplatin

Indication

Disease Entry	Status	REF
Non-small cell lung carcinoma	Investigative	[1]

Component Drugs

Indazole derivative 5 DMM1I8R

Picoplatin DM0PIY6

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HOP-92

Zero Interaction Potency (ZIP) Score: 1.43

Bliss Independence Score: 2.86

Loewe Additivity Score: 3.02

LHighest Single Agent (HSA) Score: 0.93

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Picoplatin

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[2]
Ovarian cancer	2C73	Phase 3	[2]
Prostate cancer	2C82.0	Phase 3	[2]
Small-cell lung cancer	2C25.Y	Phase 3	[2]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Anaplastic large cell lymphoma	DCTIH5X	SR	Investigative	[4]
Invasive ductal carcinoma	DC7ELMF	T-47D	Investigative	[5]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165